New insights into lung-resident memory B cells may influence the design of future vaccines to protect not only the bloodstream but also the airways, where respiratory pathogens first establish infection. According to a review published in Science Immunology on Jul. 6, researchers summarized recent advances in memory B cell biology with implications for vaccine design, emphasizing new understanding of their development, molecular regulation, tissue specialization, and function.
The review draws from over 130 studies and reviews examining diverse developmental pathways and tissue-specific behaviors of these cells. It highlights a crucial division of labor among distinct cell populations within the respiratory tract. While traditional intramuscular vaccines have been effective at preventing severe disease by training the adaptive immune system, they may be less effective at establishing long-lived localized immunity at mucosal surfaces such as the nasal cavity.
The authors say that systemic immunity is inherently less effective at stopping initial infection and transmission at mucosal barriers like those found in the respiratory tract. The review discusses how earlier views held that memory B cells mainly arose from germinal centers within secondary lymphoid organs before dispersing throughout circulation—a perspective now considered incomplete.
Recent scientific breakthroughs show that memory B cells are highly diverse and can form specialized niches within peripheral tissues to act as frontline defense against airborne pathogens. The review details advances made possible by high-dimensional omics technologies, single-cell RNA sequencing, and advanced imaging techniques, which have allowed researchers to map these processes more precisely.
The findings indicate an organized division among lung tissue-resident memory B (BRM) cell populations: one cohort sparsely populates alveoli, acting as an early frontline response with low activation thresholds—independent of helper T cells—and triggers rapid immunoglobulin G (IgG) antibody production; another cohort clusters within inducible bronchus-associated lymphoid tissue (iBALT), requiring local T cell help for a slightly delayed but targeted response producing both IgG and immunoglobulin A (IgA) antibodies.
The review concludes that spatial context significantly affects how results should be interpreted and underscores potential advantages of developing vaccines targeting airway tissues through strategies such as intranasal vaccination or "prime and spike" approaches. These strategies could recruit antigen-specific memory B cells in respiratory tissues after systemic priming. Persistent challenges remain regarding delivery consistency, durability, and variable mucosal antibody induction; however, understanding alveolar versus iBALT networks provides important guidance for engineering next-generation vaccines.
